News
EuroFlow organizes Pre-ESID workshop
In advance of the Biennal Meeting of ESID (European Society for Immunodeficiencies) in Maastricht, the Netherlands, EuroFlow organizes a an interactive workshop on the flow cytometric screening and prognostic classification of IEI-PID. This workshop is on Tuesday, 13 October from 15.00-19.30.
Spotlight on MRD Monitoring at the 15th ESLHO Symposium
We are thrilled to invite you to the 15th ESLHO Symposium ‘MRD monitoring and beyond’ that will take place on November 5 and 6, 2026 in the historic Pieterskerk in Leiden, the Netherlands.
2003 EuroClonality/BIOMED-2 publication referred to as “A landmark publication shaping hemato-oncology.”
In the recent, Jubilee Issue of Leukemia (Dec 2025), the work of the EuroClonality consortium is brought into the spotlight. In an Editorial, Andreas Hochhaus and Robert Peter Gale reflect on 40 years of scientific publications and highlight fourteen of the most cited and influential articles in the magazine.
Worldwide connection at EuroFlow MRD Course in Prague
Measurable Residual Disease (MRD) is a key factor in modern hemato-oncology. By detecting tiny numbers of remaining cancer cells after treatment — often missed by standard tests — MRD helps predict relapse and guides decisions on treatment intensity.
EQA schemes formally adopted by ESLHO
ESLHO has formally adopted the organization of the EQA schemes of EuroClonality, EuroFlow, and EuroMRD under the ESLHO EQA program. Historically, these three consortia each organized and offered their EQA programs independently.